1
|
Owens HA, Thorburn LE, Walsby E, Moon OR, Rizkallah P, Sherwani S, Tinsley CL, Rogers L, Cerutti C, Ridley AJ, Williams J, Knäuper V, Ager A. Alzheimer's disease-associated P460L variant of EphA1 dysregulates receptor activity and blood-brain barrier function. Alzheimers Dement 2024; 20:2016-2033. [PMID: 38184788 PMCID: PMC10984439 DOI: 10.1002/alz.13603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 10/11/2023] [Accepted: 11/20/2023] [Indexed: 01/08/2024]
Abstract
INTRODUCTION Genome-wide association studies link susceptibility to late-onset Alzheimer's disease (LOAD) with EphA1. Sequencing identified a non-synonymous substitution P460L as a LOAD risk variant. Other Ephs regulate vascular permeability and immune cell recruitment. We hypothesized that P460L dysregulates EphA1 receptor activity and impacts neuroinflammation. METHODS EphA1/P460L receptor activity was assayed in isogenic Human Embryonic Kidney (HEK) cells. Soluble EphA1/P460L (sEphA1/sP460L) reverse signaling in brain endothelial cells was assessed by T-cell recruitment and barrier function assays. RESULTS EphA1 and P460L were expressed in HEK cells, but membrane and soluble P460L were significantly reduced. Ligand engagement induced Y781 phosphorylation of EphA1 but not P460L. sEphA1 primed brain endothelial cells for increased T-cell recruitment; however, sP460L was less effective. sEphA1 decreased the integrity of the brain endothelial barrier, while sP460L had no effect. DISCUSSION These findings suggest that P460L alters EphA1-dependent forward and reverse signaling, which may impact blood-brain barrier function in LOAD. HIGHLIGHTS EphA1-dependent reverse signaling controls recruitment of T cells by brain endothelial cells. EphA1-dependent reverse signaling remodels brain endothelial cell contacts. LOAD-associated P460L variant of EphA1 shows reduced membrane expression and reduced ligand responses. LOAD-associated P460L variant of EphA1 fails to reverse signal to brain endothelial cells.
Collapse
Affiliation(s)
- Helen A. Owens
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
- School of DentistryCardiff UniversityCardiffUK
| | - Lauren E. Thorburn
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
- UK Dementia Research Institute, Cardiff UniversityCardiffUK
| | - Elisabeth Walsby
- Division of Cancer & GeneticsSchool of Medicine, Cardiff UniversityCardiffUK
| | - Owen R. Moon
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
| | - Pierre Rizkallah
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
| | - Subuhi Sherwani
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
| | - Caroline L. Tinsley
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
| | - Louise Rogers
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
| | - Camilla Cerutti
- School of Cellular and Molecular Medicine, University of BristolBristolUK
| | - Anne J. Ridley
- School of Cellular and Molecular Medicine, University of BristolBristolUK
| | | | | | - Ann Ager
- Division of Infection and ImmunitySchool of Medicine, Cardiff UniversityCardiffUK
- Systems Immunity University Research InstituteCardiff UniversityCardiffUK
| |
Collapse
|
2
|
Li Q, Li R, Zhu X, Chu X, An X, Chen M, Zhang L, Gao M, Chen L. EphA1 aggravates neuropathic pain by activating CXCR4/RhoA/ROCK2 pathway in mice. Hum Cell 2023:10.1007/s13577-023-00911-9. [PMID: 37162645 DOI: 10.1007/s13577-023-00911-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 04/23/2023] [Indexed: 05/11/2023]
Abstract
Neuropathic pain is a refractory disease with limited treatment options due to its complex mechanisms. Whereas erythropoietin-producing hepatocyte A1 (EphA1) mediates the production of inflammatory factors that are important in the progression of neurological diseases, its role and molecular mechanisms in neuropathic pain remain unclear. In the present study, we established a mouse model of chronic constriction injury (CCI). EphA1 expression was observed to be progressively upregulated at the mRNA and protein levels with the progression of the disease. Subsequently, knockdown of EphA1 expression levels using adenovirus short hairpin RNA (AAV-shEphA1) revealed an increase in mechanical stimulation withdrawal threshold (PWT) and withdrawal latency (PWL) when EphA1 expression was decreased, accompanied by improved dorsal root ganglion injury, increased leukocytosis, decreased microglia, and decreased levels of pro-inflammatory factors. For the underlying mechanism, it was found that EphA1 regulates the activity of the RhoA/ROCK2 pathway by modulating the level of CXCR4. Inhibition of CXCR4 and RhoA/ROCK2 could effectively alleviate the promoting effect of EphA1 upregulation on neuropathic pain. In conclusion, our study suggests that depletion of EphA1 ameliorates neuropathic pain by modulating the CXCR4/RhoA/ROCK2 signaling pathway, and targeting EphA1 may be a potential clinical treatment for neuropathic pain.
Collapse
Affiliation(s)
- Qi Li
- Department of Rehabilitation Medicine, Tianjin Hospital, Tianjin University, Tianjin, 300211, China
- Academy of Medical Engineering and Translational Medicine, Tianjin University, 92, Weijin Road, Nankai District, Tianjin, 300072, China
| | - Rui Li
- Traditional Chinese Medicine Department, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, China
| | - Xiaoxi Zhu
- Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, 550004, Guizhou Province, China
| | - Xiaolei Chu
- Department of Rehabilitation Medicine, Tianjin Hospital, Tianjin University, Tianjin, 300211, China
| | - Xiaoqiong An
- School of Basic Medical Science, Guizhou Medical University, Guiyang, 550004, Guizhou Province, China
| | - Ming Chen
- School of Basic Medical Science, Guizhou Medical University, Guiyang, 550004, Guizhou Province, China
| | - Lei Zhang
- Academy of Medical Engineering and Translational Medicine, Tianjin University, 92, Weijin Road, Nankai District, Tianjin, 300072, China
| | - Mingwei Gao
- Academy of the Society of Sport and Health Sciences, Tianjin University of Sport, Tianjin, 301617, China
| | - Long Chen
- Academy of Medical Engineering and Translational Medicine, Tianjin University, 92, Weijin Road, Nankai District, Tianjin, 300072, China.
| |
Collapse
|
3
|
Wu Y, Du Z, Mou J, Qiu X, Chen J, Cai S, Ren D, Xiao F, Zhou G, Yuan C. The Functions of EphA1 receptor tyrosine kinase in Several Tumors. Curr Med Chem 2022; 30:2340-2353. [PMID: 35996244 DOI: 10.2174/0929867329666220820125638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 05/03/2022] [Accepted: 05/16/2022] [Indexed: 11/22/2022]
Abstract
BACKGROUND Eph receptors tyrosine kinase (RTK) were identified in 1987 from hepatocellular carcinoma cell lines and were the largest known subfamily of RTK. Eph receptors can be divided into two categories, EphA and EphB, based on their structure and receptor-ligand specificity. EphA can be divided into 10 species (EphA 1-10), and EphB into 6 species (EphB1-6). Similarly, the ligands of Eph receptors are Ephrins. Ephrins also can be divided into Ephrin A and Ephrin B, of which there are five species(Ephrin-A1-5) and three species(Ephrin-B1-3). Among the Eph receptors, EphA1 has been the least studied so far. As far as we know, Eph receptors are involved with multiple pathologies, including cancer progression, tumor angiogenesis, intestinal environmental stability, the lymph node system, neurological disease, and inhibition of nerve regeneration after injury. There is a link between EphA1, integrin and ECM- related signal pathways. Ephrin-A1 is a ligand of the EphA1 receptor. EphA1 and ephrin-A1 functions are related to tumor angiogenesis. EphA1 and ephrin-A1 also play roles in gynecological diseases. Ephrin-A1 and EphA1 receptor regulate follicular formation, ovulation, embryo transport, implantation and placental formation, which are of great significance for the occurrence of gynecological tumor diseases. EphA1 has been identified as an oncoprotein in various tumors, and is associated with the prognosis of a variety of tumors in recent years. EphA1 is considered a driver gene in tumor genomics. There are significant differences in EphA1 expression levels in different types of normal tissues and tumors, and even in different stages of tumor development, suggesting its functional diversity. Changes at the gene level in cell biology are often used as biological indicators of cancer, known as biomarkers, which can be used to provide diagnostic or prognostic information and are valuable for improving the detection, monitoring and treatment of tumors. However, few prognostic markers can selectively predict clinically significant tumors with poor prognosis. These malignancies are more likely to progress and lead to death, requiring more aggressive treatment. Currently available treatments for advanced cancer are often ineffective, and treatment options are mainly palliative. Therefore, early identification and treatment of those at risk of developing malignant tumors are crucial. Although pieces of evidence have shown the role of EphA1 in tumorigenesis and development, its specific mechanism is still unknown to a great extent. OBJECTIVE This review reveals the changes and roles of EphA1 in many tumors and cancers. The change of EphA1 expression can be used as a biological marker of cancer, which is valuable for improving tumor detection, monitoring and treatment, and can be applied to imaging. Studies have shown that structural modification of EphA1 could make it an effective new drug. EphA1 is unique in that it can be considered a prognostic marker in many tumors and is of important meaning for clinical diagnosis and operative treatment. At the same time, the study of the specific mechanism of EphA1 in tumors can provide a new way for targeted therapy. METHODS Relevant studies were retrieved and collected through the PubMed system. After determining EphA1 as the research object, by analyzing research articles on EphA1 in the PubMed system in recent 10 years, we found that EphA1 was closely connected with the occurrence and development of tumors, and further determined the references according to the influencing factors for review and analysis. RESULTS EphA1 has been identified as a cancer protein in various tumors, such as hepatocellular carcinoma, nasopharyngeal carcinoma, ovarian cancer, gastric cancer, colorectal cancer, clear cell renal cell carcinoma, esophageal squamous cell carcinoma, breast cancer, prostate cancer and uveal melanoma. EphA1 is abnormally expressed in these tumor cells, which mainly plays a role in cancer progression, tumor angiogenesis, intestinal environmental stability, the lymph node system, nervous system diseases and gynecological diseases. In a narrow sense, EphA1 is especially effective in breast cancer in terms of gynecological diseases. However, the specific mechanism of EphA1 leading to the change of cancer cells in some tumors is not clear, which needs further research and exploration. CONCLUSION RTK EphA1 can be used as a biomarker for tumor diagnosis (especially a prognostic marker), an indispensable therapeutic target for new anti-tumor therapies, and a novel anti-tumor drug.
Collapse
Affiliation(s)
- Yinxin Wu
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Zhuoying Du
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Jie Mou
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Xinyan Qiu
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Jinlan Chen
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Sanjin Cai
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Dongming Ren
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Fangxiang Xiao
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
| | - Gang Zhou
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.,Yichang Hospital of Traditional Chinese Medicine, Yichang, 443002, China
| | - Chengfu Yuan
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine,State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002, China.,Medical College, China Three Gorges University, Yichang 443002, China
| |
Collapse
|
4
|
Ma J, Wang Z, Chen S, Sun W, Gu Q, Li D, Zheng J, Yang H, Li X. EphA1 Activation Induces Neuropathological Changes in a Mouse Model of Parkinson's Disease Through the CXCL12/CXCR4 Signaling Pathway. Mol Neurobiol 2021; 58:913-925. [PMID: 33057926 DOI: 10.1007/s12035-020-02122-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 09/05/2020] [Indexed: 01/12/2023]
Abstract
There is increasing evidence that EphA1 is involved in the function and development of the central nervous system, especially in neuroinflammation. It has been found to affect the disease progression of Alzheimer's disease (AD) by regulating the neuroinflammatory process. Neuroinflammation has always been regarded as the mechanism of the development of Parkinson's disease (PD) and possible therapeutic targets. Therefore, it is worth studying whether EphA1 has a potential therapeutic value for PD. The purpose of this study is to investigate the effect of EphA1 in mice and PD cell models and its mechanism.In this study, we verified the difference in expression of EphA1 and the effect and mechanism of EphA1 on neuropathological changes through Parkinson's patient samples, Parkinson's mice model, and Parkinson's model prepared from SH-SY5Y cells in vitro.EphA1 was highly expressed in the substantia nigra (SN) region of Parkinson mice and the Parkinson cell model, while the expression of tyrosine hydroxylase (TH) in the SN region of Parkinson mice was significantly reduced. After silenced EphA1 in the SH-SY5Y cell PD model, the expression levels of α-synuclein, inflammatory factors, and microglia-activated chemokine decreased. The co-immunoprecipitation experiment proved that EphA1 overexpression could promote the binding of CXCL12 and CXCR4. However, after silenced EphA1 and CXCL12 at the same time, the above effects brought by silenced EphA1 were suppressed. The same result appeared in mice with PD.EphA1 improves the inflammatory responses and neuropathological changes of the PD model in vivo and in vitro through the CXCL12/CXCR4 signaling pathway. Graphical abstract.
Collapse
Affiliation(s)
- Jianjun Ma
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China.
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China.
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China.
| | - Zhidong Wang
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Siyuan Chen
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Wenhua Sun
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Qi Gu
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Dongsheng Li
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Jinhua Zheng
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Hongqi Yang
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| | - Xue Li
- Department of Neurology, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
- People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China
| |
Collapse
|
5
|
Smith LM, Kostylev MA, Lee S, Strittmatter SM. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance. J Biol Chem 2019; 294:6042-6053. [PMID: 30787106 DOI: 10.1074/jbc.ra118.006252] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 02/18/2019] [Indexed: 11/06/2022] Open
Abstract
Oligomeric assemblies of amyloid-β (Aβ) peptide (Aβo) in the brains of individuals with Alzheimer's disease (AD) are toxic to neuronal synapses. More than a dozen Aβ receptor candidates have been suggested to be responsible for various aspects of the molecular pathology and memory impairment in mouse models of AD. A lack of consistent experimental design among previous studies of different receptor candidates limits evaluation of the relative roles of these candidates, producing some controversy within the field. Here, using cell-based assays with several Aβ species, including Aβo from AD brains obtained by autopsy, we directly compared the Aβ-binding capacity of multiple receptor candidates while accounting for variation in expression and confirming cell surface expression. In a survey of 15 reported Aβ receptors, only cellular prion protein (PrPC), Nogo receptor 1 (NgR1), and leukocyte immunoglobulin-like receptor subfamily B member 2 (LilrB2) exhibited direct binding to synaptotoxic assemblies of synthetic Aβ. Both PrPC and NgR1 preferentially bound synaptotoxic oligomers rather than nontoxic monomers, and the method of oligomer preparation did not significantly alter our binding results. Hippocampal neurons lacking both NgR1 and LilrB2 exhibited a partial reduction of Aβo binding, but this reduction was lower than in neurons lacking PrPC under the same conditions. Finally, binding studies with soluble Aβo from human AD brains revealed a strong affinity for PrPC, weak affinity for NgR1, and no detectable affinity for LilrB2. These findings clarify the relative contributions of previously reported Aβ receptors under controlled conditions and highlight the prominence of PrPC as an Aβ-binding site.
Collapse
Affiliation(s)
- Levi M Smith
- From the Program in Cellular Neuroscience, Neurodegeneration, and Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, Connecticut 06536; the Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06536
| | - Mikhail A Kostylev
- From the Program in Cellular Neuroscience, Neurodegeneration, and Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, Connecticut 06536
| | - Suho Lee
- From the Program in Cellular Neuroscience, Neurodegeneration, and Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, Connecticut 06536
| | - Stephen M Strittmatter
- From the Program in Cellular Neuroscience, Neurodegeneration, and Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, Connecticut 06536.
| |
Collapse
|
6
|
Trease AJ, Li H, Spagnol G, Zheng L, Stauch KL, Sorgen PL. Regulation of Connexin32 by ephrin receptors and T-cell protein-tyrosine phosphatase. J Biol Chem 2019; 294:341-350. [PMID: 30401746 PMCID: PMC6322898 DOI: 10.1074/jbc.ra118.003883] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Revised: 10/25/2018] [Indexed: 11/06/2022] Open
Abstract
Gap junctions are intercellular conduits that permit the passage of ions, small metabolites, and signaling molecules between cells. Connexin32 (Cx32) is a major gap junction protein in the liver and brain. Phosphorylation is integral to regulating connexin assembly, degradation, and electrical and metabolic coupling, as well as to interactions with molecular partners. Cx32 contains two intracellular tyrosine residues, and tyrosine phosphorylation of Cx32 has been detected after activation of the epidermal growth factor receptor; however, the specific tyrosine residue and the functional implication of this phosphorylation remain unknown. To address the limited available information on Cx32 regulation by tyrosine kinases, here we used the Cx32 C-terminal (CT) domain in an in vitro kinase-screening assay, which identified ephrin (Eph) receptor family members as tyrosine kinases that phosphorylate Cx32. We found that EphB1 and EphA1 phosphorylate the Cx32CT domain residue Tyr243 Unlike for Cx43, the tyrosine phosphorylation of the Cx32CT increased gap junction intercellular communication. We also demonstrated that T-cell protein-tyrosine phosphatase dephosphorylates pTyr243 The data presented above along with additional examples throughout the literature of gap junction regulation by kinases, indicate that one cannot extrapolate the effect of a kinase on one connexin to another.
Collapse
Affiliation(s)
| | - Hanjun Li
- Department of Biochemistry and Molecular Biology; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198
| | | | - Li Zheng
- Department of Biochemistry and Molecular Biology
| | | | | |
Collapse
|
7
|
Li Y, Yan H, Wang F, Huang S, Zhang Y, Wang Z, Zhong M, Zhang W. Activation of EphA1-Epha receptor axis attenuates diabetic nephropathy in mice. Biochem Biophys Res Commun 2017; 486:693-9. [PMID: 28341121 DOI: 10.1016/j.bbrc.2017.03.100] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Accepted: 03/20/2017] [Indexed: 11/21/2022]
Abstract
The Eph family of receptor tyrosine kinases serves as key modulators of various cellular functions, including inflammation, hypertrophy and fibrosis. Recent analyses have revealed that a member of the Eph family, EphA1, plays a pivotal role in regulating insulin metabolism and kidney injury. However, the importance of EphA1 in diabetic nephropathy has not been recognized. We established a diabetic nephropathy mouse model using a high-fat diet and streptozotocin (STZ) injection. Then, the recombinant adeno-associated virus type 9 (AAV9) overexpressing EphA1 or a negative control was injected locally into the kidney. Metabolite testing and histopathological analyses of kidney fibrosis, pancreatic islet function and signaling pathways were evaluated. Our study showed that hyperglycemia, insulin resistance, and renal fibrosis accompanied the deterioration of kidney function in diabetic mice. The overexpression of EphA1 in the kidney attenuated renal fibrosis and improved kidney function but did not affect systemic glucose metabolism and pancreatic islet function. Furthermore, the overexpression of EphA1 decreased the phosphorylation of ERK1/2, JNK and MYPT1 (a substrate of Rho kinase). The overexpression of EphA1 can be therapeutically targeted to inhibit diabetic renal fibrosis, which suggests that the EphA1-Epha receptor axis may be a novel therapy target for diabetic nephropathy. Mechanistically, the overexpression of EphA1 could inhibit MAPK and the Rho pathway in diabetic kidneys.
Collapse
|
8
|
Wang Y, Yu H, Shan Y, Tao C, Wu F, Yu Z, Guo P, Huang J, Li J, Zhu Q, Yu F, Song Q, Shi H, Zhou M, Chen G. EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. J Exp Clin Cancer Res 2016; 35:65. [PMID: 27066828 PMCID: PMC4827226 DOI: 10.1186/s13046-016-0339-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Accepted: 04/04/2016] [Indexed: 01/01/2023]
Abstract
BACKGROUND Endothelial progenitor cells (EPCs) can migrate to the tumor tissue and enhance the angiogenesis of hepatocellular carcinoma (HCC); thus, they are associated with a poor prognosis. However, the specific molecular mechanism underlying the homing of EPCs to the HCC neovasculature remains unrevealed. METHODS Co-culture experiments of endothelial progenitor cells with HCC cells with modulation of EphA1 were performed in vitro. Using EPCs as angiogenic promoters by injecting them into HCC xenograft-bearing nude mice via their tail veins to test homing ability of EPCs changed according to different EphA1 level in HCC xenograft. RESULTS In this study, we found that the up-regulation of EphA1 expression in HCC cells could affect not only the chemotaxis of EPCs to tumor cells and endothelial cells (ECs) but also the tube formation ability of EPCs in a paracrine fashion. Further, we revealed that the increased expression of EphA1 in HCC cells led to an increased SDF-1 concentration in the tumor microenvironment, which in turn activated the SDF-1/CXCR4 axis and enhanced the recruitment of EPCs to HCC. In addition, the EphA1-activated SDF-1 expression and secretion was partially mediated by the PI3K and mTOR pathways. In vivo experiments demonstrated that blocking EphA1/SDF-1/CXCR4 signaling significantly inhibited the growth of HCC xenografts. Using immunohistochemistry and immunofluorescence assays, we verified that the inhibition of tumor angiogenesis was at least partially caused by the decreased number of EPCs homing to tumor tissue. CONCLUSIONS Our findings indicate that targeting the EphA1/SDF-1 signaling pathway might be a therapeutic anti-angiogenesis approach for treating HCC.
Collapse
Affiliation(s)
- Yi Wang
- Environmental and Public Health School of Wenzhou Medical University, Wenzhou, 325000, China
| | - Haitao Yu
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Yunfeng Shan
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Chonglin Tao
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Fang Wu
- Department of Gastroenterology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Zhengping Yu
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Pengyi Guo
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Jianfei Huang
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Junjian Li
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Qiandong Zhu
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Fuxiang Yu
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Qitong Song
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Hongqi Shi
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China
| | - Mengtao Zhou
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China.
| | - Gang Chen
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, China.
| |
Collapse
|
9
|
Wang X, Liu Y, Cao G, Zhang X, Xu H, Xu H, Wang J. Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Pathol 2015; 8:6821-6827. [PMID: 26261568 PMCID: PMC4525902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Accepted: 05/26/2015] [Indexed: 06/04/2023]
Abstract
Aberrant expression of receptor tyrosine kinase EphA1 in malignant tissues has been reported. However, the expression profile of EphA1 in renal cell carcinoma (RCC) and its association with clinicopathological parameters remain unknown. The aim of this study was to determine the cancerous value of the EphA1 protein expression in patients with renal cell carcinomas. This study included 144 patients with clear cell RCC (ccRCC), 18 patients with chromophobe RCC and 6 patients with papillary RCC. The EphA1 protein was detected in RCC tissue samples by an immunohistochemical staining with a specific polycolonal antibody. The correlation of the expression of the EphA1 protein with clinicopathological parameters was evaluated. High level of the expression of EphA1 was observed in all normal renal tubes. The EphA1 protein was negatively or weakly expressed in 93 out of 144 ccRCC (64.6%) and positively expressed in 51 out of 144 ccRCC (35.4%). The high level expression of the EphA1 protein was significantly associated with younger patients (P<0.001), sex (P=0.016) and lower nuclear grade (P<0.001). No significant relation between the expression of EphA1 and tumor diameter was found (P=0.316). Positive expression of EphA1 was observed in all samples of chromophobe RCC and papillary RCC. Our data indicated that the EphA1 protein may be a new marker for the prognosis of ccRCC.
Collapse
Affiliation(s)
- Xiaolin Wang
- Department of Urology, Nantong Tumor HospitalNantong 226361, Jiangsu, China
| | - Yushan Liu
- Department of Pathology, Nantong Tumor HospitalNantong 226361, Jiangsu, China
| | - Guangxin Cao
- Department of Urology, Nantong Tumor HospitalNantong 226361, Jiangsu, China
| | - Xueliang Zhang
- Department of Urology, Nantong Tumor HospitalNantong 226361, Jiangsu, China
| | - Haifei Xu
- Department of Urology, Nantong Tumor HospitalNantong 226361, Jiangsu, China
| | - Hanfeng Xu
- Department of Oncology, Second Affiliated Hospital, Southeast UniversityNanjing 210003, Jiangsu, China
| | - Jiandong Wang
- Department of Pathology, Jinling HospitalNanjing 210002, China
| |
Collapse
|
10
|
Peng L, Wang H, Dong Y, Ma J, Wen J, Wu J, Wang X, Zhou X, Wang J. Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol 2013; 6:1854-1860. [PMID: 24040450 PMCID: PMC3759492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 08/12/2013] [Indexed: 06/02/2023]
Abstract
The erythropoietin-producing hepatocellular (Eph) family of receptor tyrosine kinases regulates a multitude of physiological and pathological processes. EphA1 is the first member of Eph superfamily and is involved in carcinogenesis. The aim of this study was to investigate the expression of EphA1 in prostate cancers cell lines and the tissues, then explore the correlation with the clinicopathologic parameters. The EphA1 transcript expression in prostate cancer cell lines was detected by Quantitative real-time PCR. The expression of EphA1 protein in 138 prostate cancer tissue samples and 21 benign prostate hyperplasia samples were checked by using immunohistochemical staining. EphA1 mRNA was high expressed in LNCap, moderately expressed in 22RV1 and Du145, and lost in PC3. Loss of expression of EphA1 transcript was related to hypermethylation of CpG island around the translation start site. EphA1 protein was differentially expressed in prostate cancers and hyperplasia. Increased expression of EphA1 protein was more frequently detected in prostate cancers than in hyperplasia (P = 0.02), and more often detected in prostate cancer with high Gleason score (P < 0.001). Our data indicate that EphA1 receptor may have roles in carcinogenesis and progression of prostate cancer, and can be a potentially useful target for prognostic and therapeutic application.
Collapse
Affiliation(s)
- Libo Peng
- Southern Medical UniversityGuangzhou, China
- Clinical Medical School of Southern Medical UniversityNanjing, China
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Haiyan Wang
- Southern Medical UniversityGuangzhou, China
- Clinical Medical School of Southern Medical UniversityNanjing, China
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Yingchun Dong
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Jie Ma
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Juanjuan Wen
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Jinrong Wu
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Xueqing Wang
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Xiaojun Zhou
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| | - Jiandong Wang
- Southern Medical UniversityGuangzhou, China
- Clinical Medical School of Southern Medical UniversityNanjing, China
- Department of Pathology, Jinling Hospital, Nanjing University School of MedicineNanjing, China
| |
Collapse
|